Aurinia Pharmaceuticals Inc
AUPH - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.11B
Close$
$7.01
55.5% downside
Current Fair Value
55.5% downsideOvervalued by 55.5% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $2.11 Billion |
|---|---|
| Enterprise Value | $2.13 Billion |
| Earnings per Share | $2.14 |
| Beta | 1.41 |
| Outstanding Shares | 133,434,000 |
Return
| Return on Equity | 47.80% |
|---|---|
| Return on Assets | 38.06% |
| Return on Invested Capital | 23.70% |
Valuation & Multiples
| P/E Ratio | 6.64 |
|---|---|
| PEG | 1377.68 |
| Price to Sales | 7.87 |
| Price to Book Ratio | 3.93 |
| Enterprise Value to Revenue | 6.62 |
| Enterprise Value to EBIT | 12.32 |
| Enterprise Value to Net Income | 6 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.11 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 3, 2026
EPS Estimate
$0.22
Consensus analyst estimateRevenue Estimate
$83.61 M
Consensus analyst estimateNext Earnings Call
Expected Date
February 25, 2027
EPS Estimate
$0.24
Consensus analyst estimateRevenue Estimate
$85.13 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 353.81% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 4.91%▼ 55.05% |
|---|---|
| Total Invested | $103.45M▼ 92.32% |
| Investors Holding | 73▼ 221.00% |
About Aurinia Pharmaceuticals Inc
CEO: Peter Greenleaf
